Experience of use of the anti-cytokine drug adalimumab in children with polyarticular seronegative junior arthritis living in the Samara region
Experience of use of the anti-cytokine drug adalimumab in children with polyarticular seronegative junior arthritis living in the Samara region
Blog Article
Background.Juvenile idiopathic arthritis is the most common rheumatic disease in childhood.Adalimumab is the drug of choice for polyarthritis, HLA-B27-associated arthritis, psoriatic arthritis, as well as for the association of arthritis with enthesitis, uveitis.
It is of interest to evaluate the efficacy and safety of the genetically engineered biological drug adalimumab in patients with polyarticular rheumatoid factor seronegative juvenile idiopathic arthritis living in the Samara region.Objective.The aim of the study is to evaluate the efficacy and safety of the genetically engineered biological drug adalimumab in patients with polyarticular seronegative juvenile idiopathic arthritis in the Russian Federation living in Crutch Accessories the Samara region.
Materials and methods.A retro- and prospective study of 32 (8 boys, 24 girls) patients with polyarticular juvenile idiopathic arthritis, seronegative in the Russian Federation, was carried out.The disease was diagnosed using the ILAR diagnostic criteria.
The study was conducted from 2018 to 2022 on the basis of the Samara Regional Clinical Cardiological Dispensary V.P.Polyakov.
Analysis of the effectiveness of Engravable Bead Name Cuff Bracelet With Birthstone the therapy was carried out during 6 visits with an interval of 70 days and included an assessment of the functional ability using the CHAQ questionnaire.The indicators of the effectiveness of therapy included: achievement of 50-90% improvement in drug remission of the disease.Results.
Efficacy, safety, and good tolerability of the anticytokine genetically engineered biological drug adalimumab in the treatment of children with polyarticular seronegative juvenile idiopathic arthritis in the Russian Federation have been proven.Conclusion.The results obtained allow us to conclude that it is reasonable to use adalimumab in patients with refractoriness to immuno-suppressive therapy used for the treatment of juvenile arthritis and consider this approach promising in pediatric rheumatology.